Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average recommendation of “Hold” from the seven brokerages that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $4.94.
CARM has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Evercore ISI reissued an “in-line” rating and set a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. BTIG Research cut shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Finally, Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th.
Check Out Our Latest Analysis on Carisma Therapeutics
Institutional Trading of Carisma Therapeutics
Carisma Therapeutics Stock Performance
Shares of CARM opened at $0.50 on Friday. Carisma Therapeutics has a 12-month low of $0.38 and a 12-month high of $2.77. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The company has a market cap of $20.83 million, a PE ratio of -0.32 and a beta of 1.56. The stock has a 50-day moving average price of $0.55 and a 200-day moving average price of $0.86.
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The business had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. As a group, equities analysts forecast that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
Read More
- Five stocks we like better than Carisma Therapeutics
- What is the Nasdaq? Complete Overview with History
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Roth IRA Calculator: Calculate Your Potential Returns
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.